Tweet
Originally posted by spikefader
Still looking for 10.00 out of it. But I wouldn't be holding long or short for the halt and announcement unless appropriately hedged. Good luck dudes!
-
Love you guys for teaching me about stops!! -
An open letter to the membership of the National Multiple Sclerosis Society from Joyce Nelson, President & CEO
March 5, 2006—People with multiple sclerosis must have more choices for safe and effective treatments. The National MS Society is relentless in our pursuit of this goal.
It is our strongest hope that the FDA, after considering the safety issues associated with Tysabri®, will determine that such issues are manageable and that Tysabri can return to the market.
To that end, the National Multiple Sclerosis Society has worked on multiple fronts to assist the FDA with its work:
We advocated for the speediest possible review of Tysabri. As a result, the FDA accelerated the process to the fastest extent the law would permit.
In order to assure that the FDA received feedback from every individual who wished to be heard on this issue, we dedicated a month-long front-page link from our website, which attracts over 14.5 million visits a year, to the FDA comment page. We also provided information on submitting testimony and participating in the hearings in person. As a result of the outpouring from all comments received, the FDA extended its hearing proceedings from one day to two, and expanded its usual one to two hour public comment period to six.
In order to make sure that the hopes and concerns of people with MS were being heard in the FDA process, in December 2005, the National MS Society commissioned an online survey of people with MS to better understand their views concerning Tysabri and its possible return to market. The Society shared the comprehensive results of that survey with the FDA, who will include these results in their deliberations.
In order to assure that the best possible reviewers serve on the FDA panel, the National Multiple Sclerosis Society met with FDA officials and submitted a recommended list of reviewers who, in our opinion, bring to the table a comprehensive and balanced understanding of the issues associated with the return of Tysabri to the market. We do not know if any of these candidates will ultimately sit on the review panel, but the FDA accepted these recommendations for consideration.
Dr. John Richert, Vice President of Research and Clinical Programs, will present testimony at the hearings March 7-8 and will attend the full deliberations, along with other Society officials. Dr. Richert's statement will be made available on our website after his testimony on March 7.
Since Tysabri's initial introduction to the market and its subsequent recall, the Society has provided the most current and comprehensive information available to its membership on this important issue.
During this time, a number of Society members have become actively engaged in advocating for specific outcomes. We encourage and support each of our members in their right to take an individual stand on this issue, and we support the rights of members to form ad hoc groups to support their opinion.
We have maintained respectful communications with these members. For example, as a result of the work of MS Patients for Choice, Society members had the opportunity to register for the webcast of the hearing at a fraction of the full cost.
The Society has a responsibility to give voice to all people affected by MS—those hoping for more effective treatment and those concerned with having safe treatment choices. Thus, despite the urgings of individuals, industry representatives and ad hoc groups representing all points of view on this matter, the National Multiple Sclerosis Society has not, and will not, dictate to the FDA what its answer should be.
Having provided the best possible information and feedback to the FDA, we support the process that has been designed to review Tysabri. If, after this safety review is complete, the FDA recommends Tysabri's return to the market, we will applaud the addition of this treatment to our arsenal. If the FDA does not approve Tysabri's return to the market, or if it does so with significant restrictions, we will work tirelessly to find ways to satisfy the safety concerns so that more effective treatments can be readily available for the benefit of people with MS.Comment
-
Spike, just wondering when and if (i'm sure you did) close out your position on ELN?Originally posted by spikefaderStill looking for 10.00 out of it. But I wouldn't be holding long or short for the halt and announcement unless appropriately hedged. Good luck dudes!
Comment
-
Yep, I did. The first short I took +16% http://www.mrmarketishuge.com/showpo...postcount=1084 and the second short looked good as it went +3% AH, but then opened higher and I took my -4% exit http://www.mrmarketishuge.com/showpo...postcount=1120Originally posted by dmk112
Now I'm lurkin'. I may short for a daytrade tomorrow if it sets up right but if it doesn't I may consider bidding low after it after the halt is over and see if I can't buy support well. I dunno where for sure yet, but contemplating 10.25 for a nibble so I don't get too hurt if it acts wrong at the open. I'll try to post anything I'm seeing. Who knows....it may just gap up after the halt and run like a little monkey....but I'd be a very uncomfortable long if I weren't hedged well....the chart, she's a whisperin' lower to me....Comment
-
I'll hedge myself by selling 2/3 of my ELN off today. I already sold 1/2 off on when it doubled. je,je,jeComment
-
Webs,Originally posted by Websman
Here's a variable. After two days they come out and say, " our evidence is inconclusive and we need more time", which would be in line with everything else they do when it comes time to make a decision on something important. Then they reschedule the announcement for sometime in August. I say it's 50/50 they make they specifically make the announcement one way or another.THE SKIRACER'S EDGE: MAKE THE EDGE IN YOUR FAVOR
Comment
-
Now I'm lurkin'. I may short for a daytrade tomorrow if it sets up right but if it doesn't I may consider bidding low after it after the halt is over and see if I can't buy support well. I dunno where for sure yet, but contemplating 10.25 for a nibble so I don't get too hurt if it acts wrong at the open. I'll try to post anything I'm seeing. Who knows....it may just gap up after the halt and run like a little monkey....but I'd be a very uncomfortable long if I weren't hedged well....the chart, she's a whisperin' lower to me....[/QUOTE]
I was thinking the same to place low bid in and just see. I may also buy a small position before todays close just in case the monkey does run.This stock is acting so very strange. I still believe this is going to be 'A REEEELY BIG SHEW... REELY BIG!" (just dated myselft there) So I may just buy low and forget about it for a longish' hold investment.
(spike, If you gonna wear that cat suit, I'll take you in on any cold night. Even let you nap on my bed along with BlackJack and Casper.)
(oliver and Gabby prefer to sleep downstairs) Robert (my husband) sleeps outside. hehehe
"Whatever you can do or dream you can , begin it. Boldness has genius,power and magic in it." GoetheComment
-
-
Sold all of my ELN for a huge profit...jejejejeComment
-
Great news for you ELN fans:
of course, if PRX's Flonase battle is any indication, the stock will drop 3% from this news when it resumes trading...
FDA Panel Supports MS Drug's Market Return
Wednesday March 8, 11:24 am ET FDA Panel Unanimously Supports MS Drug Tysabri's Return to U.S. Market
WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should allow multiple-sclerosis drug Tysabri back on the market.
The drug's manufacturers, Biogen Idec Inc. and Elan Corp., pulled the drug in February 2005 after two patients developed a rare brain disorder, known as progressive multifocal leukoencephalopathy, or PML, and one died. A third patient was later discovered to have PML and also died.
The 12-member panel voted unanimously to support the drug's return.
The FDA usually follows its panel's advice, but isn't required to do so. The agency is expected to make a final decision by the end of the month.Comment
-
Yo Spike.... We shall see if Webs "bucking the VTP" was such a HUUUUGE!!!! move or not.je....je....jeOriginally posted by spikefaderCongratulations Webs! Dude it was a Huge trade worthy of some accolades.
BEEF!... it's whats for dinner!Comment
-
Webs may have suffered from premature exitation on this one. After holding from so long to have exited right at the wire. But who knows.Originally posted by LyehopperTHE SKIRACER'S EDGE: MAKE THE EDGE IN YOUR FAVOR
Comment
-
hehe ya.....hey what is the VTP's reading on ELN right now? I note Webs indicated the VTP said it was in a bearish trend recently, then he went long ELN for a couple pennies for POTW, and now sold his full position for something like +100% profit (which no one else has congratulated him for I see
).......so can the VTP predict the bias of this surely volatile opener?
Comment
Glad to hear it sister! One obviously saved you from some pain. Good fer you and thnx fer sharin'. One can always reenter! 
Comment